Clinical Trial

A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the effectiveness and safety of ozanimod in Chinese adults with relapsing multiple sclerosis.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-04-29; most recent amendment 2025-04-15.
Status change: Recruiting → Active, Not Recruiting 2025-04-15
Status change: Not Yet Recruiting → Recruiting 2024-06-05
Trial Details
NCT Number NCT06396039
Lead Sponsor Bristol-Myers Squibb
Conditions Relapsing Multiple Sclerosis
Enrollment 84 participants
Start Date 2024-05-15
Primary Completion 2028-12-29 (estimated)
Study Completion 2029-03-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-16